Espansione Group

27/11/2025

We’re looking forward to seeing you all at FLORetina 2025.

After achieving great resonance in Anterior Segment care, we are bringing our core light-based technology LM™ LLLT Photobiomodulation (PBM) to the back of the eye.

If you share our ambition to slow down progression of the disease, stop by 📍 Booth #56 and join us on our mission to advance non-invasive management of Age-related Macular Degeneration.

📅 Curious to learn more?
👇 Don’t miss this year’s faculty sessions on our technology.

Dr. Claudio Iovino
"12-Months Outcomes of PBM in Intermediate AMD: A Prospective Multicenter Randomized Controlled Clinical Trial

🗓️ Saturday, December 6th
🕒 14:28
📍 San Giovanni Room

Dr. Mariapia Laterza
"Photobiomodulation-induced Choriocapillaris Perfusion Enhancement and Outer Retinal Remodelling in Intermediate Age-Related Macular Degeneration: a Promising Therapeutic Approach with Short-term Results"

🗓️ Sunday, December 7th
🕒 10:09
📍 Del Carmine Room

⚡️One more thing...

This year at FLORetina 2025 we’re joined by our colleagues from EssilorLuxottica, Heidelberg Engineering and Retinai .

👉 Come and join us in shaping what’s next in ​ophthalmology—we can’t wait to see you all in Florence.

06/11/2025

The ocular microbiome is central to ocular surface health, and Demodex infestation is a major driver of blepharitis and dry eye disease.

A new peer-reviewed study (Farrant S. et al., Clin Ophthalmol. 2025) demonstrates the effectiveness of eye-light® combining OPE™ IPL and LM™ LLLT (blue + red light) in managing treatment-resistant Demodex blepharitis.

Key outcomes:
✅ Significant reduction in collarettes & saponification
✅ Improved ocular surface parameters (CFS, hyperemia)
✅ Symptom relief (DEQ-5 ↓ from 12.0 → 7.8)
✅ No adverse events reported

By targeting both mite eradication and ocular surface health, our light-based protocol offers a comprehensive, safe, and patient-friendly solution for Demodex blepharitis.

At Espansione, we remain committed to advancing evidence-based innovation in ophthalmology.

23/10/2025

A breakthrough in ocular surface protection: results from a randomized, double-masked trial highlight the effectiveness of LM™ LLLT (PBM) in reducing Iatrogenic Dry Eye Disease after cataract surgery.

Conducted on a real-life surgical cohort, the therapy was safe, feasible to implement perioperatively, and readily adaptable to standard cataract surgery protocols.

The study found statistical significance in the following results:
✅ Improvements in OSDI and tear film break-up time
✅ Stabilization of tear osmolarity
✅ Preservation of corneal epithelial integrity

This reinforces the importance of device-based, non-invasive therapies in modern ophthalmology and sets a foundation for the integration of LM™ LLLT into routine surgical care.

Acknowledging the outstanding work of the authors: Mihaela-Madalina Timofte-Zorila, Daniel Constantin Branisteanu & team.

14/10/2025

This weekend in Taunton reminded us of the power of collaboration and shared expertise.

Our sincere thanks to Rodenstock Norway and Olav Bjella Stavn for bringing together an engaged group of Norwegian optometrists and to Dr. Sarah Farrant for welcoming everyone into her clinic and sharing her clinical experience with eye-light® and Light Modulation™ LLLT.

From theory to real-world application, participants had the opportunity to witness firsthand how light-based therapies are transforming the management of dry eye and ocular surface diseases — guided by Dr. Farrant's deep expertise and daily clinical practice.

Our warmest thanks to Dr. Sarah Farrant for opening her doors and sharing her insights, to Rodenstock and Olav Bjella Stavn for their amazing collaboration, to our one and only Riccardo Nicoletti for being our rock, and to all participants for bringing their enthusiasm and curiosity.

Together, we continue to advance science-based innovation in eye care.

14/09/2025

11/09/2025

🔬 1 Day to Go | Join Us at ESCRS 2025
📍 Hall C · Booth C1.180

Tomorrow at ESCRS, we launch the InSight Speech Series—a daily program of live scientific talks hosted at our booth, featuring leading voices in ocular innovation.

🎤 Join Prof. Giannaccare, Dr. Daya, Prof. Wolffsohn, Dr. Trave-Huarte, Prof. Piñero, Dr. Stonecipher, Dr. Timofte, Dr. Valdez-Garcia and others as they share clinical insights on:
✅ TFOS DEWS III Report & Dry Eye
✅ Surgical outcomes & post-op DED
✅ Ocular microbiome & LLLT
✅ Demodex blepharitis
✅ PBM for AMD: multicentric data
✅ Screening innovation in ocular surface care

Whether you’re focused on the ocular surface or retinal therapy, this is where science meets practice—live.

👉 View the full agenda & add to your calendar:
https://espansionegroup.it/espansione-group-at-escrs-2025/

Let’s move science forward.
See you tomorrow at Booth C1.180.

04/09/2025

Just one day to go—discover one of the standout session of the Euretina 2025 Congress.

You're invited to join our expert-led symposium:

Light Modulation™ LLLT (PBM): A New Frontier in Retinal Care & Beyond
🗓 September 5th | 🕔 17:45–18:45
📍 Amphithéâtre Havane, Level 3, Le Palais des Congrès, Paris

🎓 Speakers: Prof. Giannaccare | Prof. Demirel | Prof. Borrelli | Dr. Iovino | Dr. Viggiano
🎤 Moderators: Dr. Bacherini | Prof. Zur | Prof. Mastropasqua

In this one-hour session, we’ll explore the science, mechanisms, and clinical evidence behind PBM as a non-invasive therapeutic strategy for Dry Age-related Macular Degeneration and beyond.

Also happening at Euretina 2025:
- Prof. Borrelli (Italy) ePoster: 12-Month Efficacy of Photobiomodulation Treatment in Dry Age-Related Macular Degeneration Using the eye-light® Device” | ePoster & Video Terminals on Level 3

🔗 Explore the full program and join us in Paris to discover the future of light-based retinal therapy.

📌 Visit us throughout the congress at EssilorLuxottica Booth 3.A25

28/08/2025

🔬 ESCRS 2025 | InSight Speech Series at Booth C1.180

This ESCRS, experience the power of real-world clinical insight—right from the show floor.
Every day, leading KOLs will present breakthrough insights on photobiomodulation—from TFOS DEWS III Report and pre-/post-surgery DED, to ocular microbiome, Demodex and retinal care.

Meet the experts driving innovation in ocular surface management and retinal care: Prof. G. Giannaccare, Dr. S. Daya, Prof. J. Wolffsohn, Dr. S. Travé-Huarte, Prof. D. P. Piñero, Dr. K. Stonecipher, Dr. M. Timofte, Dr. A. Losada Rodriguez, Dr. J. E. Valdez-Garcia and others.

This is not just another booth—it’s a daily space for scientific exchange.
📍 Booth C1.180 | Hall C

Add to your calendar:
https://espansionegroup.it/espansione-group-at-escrs-2025/

31/07/2025

🔬 Where Light Meets Science

Join us at ESCRS 2025—Hall C, Booth C1.180—your destination for in-depth exchange with world-leading experts.

Every day, our InSight Speech Series brings thought leaders to the booth to share cutting-edge research and clinical insights on our technologies.

Dive into the future of anterior segment care and photobiomodulation with discussions on Dry Eye Disease and postoperative DED management, the recent TFOS DEWS III Report, Demodex Blepharitis and more.

Real science. Real results. Straight from the experts.

We look forward to welcoming you in Copenhagen.

Discover More Now!
👉https://espansionegroup.it/espansione-group-at-escrs-2025/

29/07/2025

🔬 Innovation meets Science at Euretina 2025

From September 4th to 7th, join us at the EssilorLuxottica Booth (3.A25) to discover how Light Modulation™ LLLT (PBM) is redefining retinal care.

Photobiomodulation is at the forefront of early, non-invasive management of degenerative retinal conditions such as Age-related Macular Degeneration (AMD).

If you’re keen to dive deeper, don’t miss our symposium on the expanding role of PBM in retinal therapeutics and join the conversation with top-tier KOLs (Prof. Enrico Borrelli | Dr. Claudio Iovino | Dr. Pasquale Viggiano | Prof. Sibel Demirel | Prof. Giuseppe Giannaccare) and stellar moderators (Dr. Daniela Bacherini, Dr. Dinah Zur, Dr. Rodolfo Mastropasqua).

📅 September 5 | 🕔 17:45–18:45
📍 Amphithéâtre Havane, Le Palais des Congrès, Paris

Let’s connect in Paris to shape the future of light-based ophthalmic care.

23/07/2025

As July sheds light on Dry Eye Awareness Month, we take a moment to recognize World Sjögren’s Day, and the unique challenges faced by patients suffering from this autoimmune disease.

Often, these individuals experience severe symptoms that don’t respond to traditional treatments.

📑 That’s where science steps in.
In a 2021 study, Di Marino et al. demonstrated that the combination of OPE™ IPL and LM™ LLLT, delivered via our eye-light® platform, can significantly improve the evaporative component of DED in patients with ’s Syndrome.

We’re proud to support the clinical community in rethinking how we manage complex ocular surface diseases—through , , therapeutics.

22/07/2025

As we advance in Awareness Month, our momentum continues.
A few weeks after our recognition by (Tear Film & Ocular Surface Society) within the DEWS III Report, an acknowledgment confirming the potential of light therapy within the dry eye disease (DED) management challenge has been published by Tan et al. on Current Opinion in Ophthalmology.

The study dives deeper on the potential of as a rising standard in ophthalmology.

🧬 Espansione Group’s eye-light® platform and LM™ LLLT (PBM) technology are featured across a wide array of trials, covering both the front and the back of the eye, reinforcing our leading role in light-based, non-invasive therapeutics in eye care.

There’s still a lot to be done, but everything counts towards giving everyone access to non-invasive, painless management tools of ophthalmic diseases.

Thanks to the authors for this piece of work and paving the way for what will be next in this field. Chris L., Raymond P. Najjar, PhD, Giuseppe Giannaccare

🔗 Access the publication: https://pubmed.ncbi.nlm.nih.gov/40471752/